Critical Review: BioSig Technologies (NASDAQ:BSGM) vs. NeurAxis (NASDAQ:NRXS)

Institutional and Insider Ownership

7.2% of BioSig Technologies shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 9.3% of BioSig Technologies shares are owned by company insiders. Comparatively, 15.2% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

BioSig Technologies has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 4.27, suggesting that its stock price is 327% more volatile than the S&P 500.

Earnings & Valuation

This table compares BioSig Technologies and NeurAxis”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioSig Technologies	$20,000.00	1,670.18	-$29.04 million	N/A	N/A
NeurAxis	$2.46 million	9.24	-$14.63 million	($1.84)	-1.77

NeurAxis has higher revenue and earnings than BioSig Technologies.

Profitability

This table compares BioSig Technologies and NeurAxis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioSig Technologies	-44,832.50%	N/A	-776.49%
NeurAxis	-492.76%	N/A	-641.25%

Summary

NeurAxis beats BioSig Technologies on 7 of the 8 factors compared between the two stocks.

About BioSig Technologies

BioSig Technologies, Inc., together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.